Nasdaq · CIK 0001226616
MNOV MEDICINOVA INC
Insider trading from SEC Form 4. Last filing 14 d ago. Close $1.52 on Oct 9, 2026, +29% from the 52-week low and -56% from the high.
In brief
MEDICINOVA INC (MNOV) has 12 SEC Form 4 filings on file from 6 insiders, the latest filed on Sep 29, 2026. In the last 90 days insiders made 0 open-market buys worth $0 and 1 open-market sell worth $1.7M, net -$1.7M.
1 open-market trade has been scored at MNOV. The newest: 3D Investment Partners Pte. Ltd. sold $1.7M of stock on Sep 25, 2026, filed Sep 29, 2026, scored 38 (weak).
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at MEDICINOVA INC, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 38Weak | 3D Investment Partners Pte. Ltd. other sell | $1.7M 640,000 shares | -12% | - |
Transactions
Every row filed, 12 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 25, 2026 | 3D Investment Partners Pte. Ltd. other | SOpen-market sale Common Stockindirect: As Investment Manager to 3DOMF | -640,000 | $2.70 | $1.7M | 4,862,047 | 14 d ago |
| Jun 23, 2026 | Carolyn Beaver director | AGrant or award Stock Option (Right to Buy)derivative | +44,500 | $0.00 | $0 | 44,500 | Jun 25, 2026 |
| Jun 23, 2026 | Nicole Lemerond director | AGrant or award Stock Option (Right to Buy)derivative | +44,500 | $0.00 | $0 | 44,500 | Jun 25, 2026 |
| Jun 23, 2026 | Hideki Nagao director | AGrant or award Stock Option (Right to Buy)derivative | +44,500 | $0.00 | $0 | 44,500 | Jun 25, 2026 |
| Jan 16, 2026 | Yuichi Iwaki President and CEO | AGrant or award Employee Stock Option (Right to Buy)derivative | +450,000 | $0.00 | $0 | 450,000 | Jan 20, 2026 |
| Jan 16, 2026 | Kazuko Matsuda Chief Medical Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +350,000 | $0.00 | $0 | 350,000 | Jan 20, 2026 |
| Jun 17, 2025 | Carolyn Beaver director | AGrant or award Stock Option (Right to Buy)derivative | +20,000 | $0.00 | $0 | 20,000 | Jun 20, 2025 |
| Jun 17, 2025 | Nicole Lemerond director | AGrant or award Stock Option (Right to Buy)derivative | +20,000 | $0.00 | $0 | 20,000 | Jun 20, 2025 |
| Jun 17, 2025 | Hideki Nagao director | AGrant or award Stock Option (Right to Buy)derivative | +20,000 | $0.00 | $0 | 20,000 | Jun 20, 2025 |
| Feb 12, 2025 | Carolyn Beaver director | AGrant or award Stock Option (Right to Buy)derivative | +24,500 | $0.00 | $0 | 24,500 | Feb 14, 2025 |
| Feb 12, 2025 | Yuichi Iwaki President and CEO | AGrant or award Employee Stock Option (Right to Buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Feb 14, 2025 |
| Jan 7, 2025 | Yuichi Iwaki President and CEO | AGrant or award Employee Stock Option (Right to Buy)derivative | +400,000 | $0.00 | $0 | 400,000 | Jan 10, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- 3D Investment Partners Pte. Ltd.other
- Carolyn Beaverdirector
- Yuichi IwakiPresident and CEO
- Nicole Lemeronddirector
- Kazuko MatsudaChief Medical Officer
- Hideki Nagaodirector
Questions about MNOV
Answered from the filings on this page, as of the latest one.
Are insiders buying MNOV?
As of Sep 29, 2026, SEC Form 4 filings show 0 open-market buys worth $0 by 0 insiders and 1 open-market sell worth $1.7M by 1 insider at MEDICINOVA INC in the last 90 days, net -$1.7M. Only purchases (code P) and sales (code S) count; grants, option exercises and tax withholding do not.
Who was the last insider to trade MNOV on the open market?
3D Investment Partners Pte. Ltd. sold $1.7M of MNOV on Sep 25, 2026 and filed the Form 4 on Sep 29, 2026. InsiderTell scored 38 (weak).
How many insiders file Form 4 at MEDICINOVA INC?
6 people have filed a Form 4 at MEDICINOVA INC, among them 3D Investment Partners Pte. Ltd. (insider), Carolyn Beaver (director), Yuichi Iwaki (President and CEO). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.